AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

Bioshares 970 1AD extract.pdf

AdAlta’s decision to accelerate the implementation of its “East to West” strategy, which is seeing the company focus on licensing cell therapy products from Asia (China especially) for Western markets has received BIOSHARES’ tick of approval.

The respected biotech investment site highlights the factors driving the strategy, including the high number and quality of T-cell therapies being developed in China now wanting an entrée into Western markets, and the skill sets of both AdAlta’s highly experienced leadership team and its collaborating partner, Synthesis Bioventures.

BIOSHARES succinctly explains how cell therapy assets identified by AdAlta are progressing through due diligence process and how AdAlta business unit AdCella will raise the funds to conduct drug candidate development works. AdAlta anticipates three to six venture capital investors will participate in the first outside funding round of AdCella.

BIOSHARES has a favourable view on AdAlta’s “East to West” strategy, issuing a Speculative Buy Class B recommendation on the company.

BIOSHARES: Leading the Way – Adalta's East to West Strategy